3I & Cathay Capital take majority stake in Havea

3i Group, a London‑listed private equity firm, agreed to invest EUR 150 million in Ponroy Santé (now Havea) to acquire a controlling stake in the French natural‑consumer‑health platform, with Cathay Capital Partners taking a minority co‑investment alongside. The transaction is structured as a leveraged buy‑out in which 3i becomes the majority shareholder while the founding shareholder Arnaud Ponroy and CEO Fabrice Cahierc maintain meaningful equity stakes, preserving continuity of management and entrepreneurial alignment. Under the deal, Philippe Charrier joins as Executive Chairman and minority shareholder, bringing international healthcare and consumer‑goods experience from prior leadership roles at Oenobiol, Labco, and Procter & Gamble France. The EUR 150 million commitment is intended to accelerate both organic and external growth, including the pursuit of bolt‑on acquisitions in the fragmented natural‑health and consumer‑healthcare space, with a strategic focus on consolidating mid‑tier brands and expanding distribution density in priority markets.